MedTrace Logo

Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis

NCT05650060 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 163

Last updated 2023-04-06

No results posted yet for this study

Summary

This study was a non-interventional, retrospective study collecting data from hospital medical records. Approximately 200 adult patients with moderate to severe plaque psoriasis who were treated with secukinumab from hospitals in Thailand that participated in this study were expected for data collection.

Conditions

Interventions

DRUG

Secukinumab

all patients with psoriasis who received secukinumab

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-20
Primary Completion
2021-12-23
Completion
2021-12-23

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05650060 on ClinicalTrials.gov